Vaxxas today announced a $22 million United States government award to support the deployment of Vaxxas’ proprietary HD-MAP technology platform in response to pandemic threats to public health.
The award is funded through the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services, and is aimed at advancing clinical demonstration of Vaxxas’ proprietary HD-MAP patch for pandemic influenza. Aligned with this approach, Vaxxas is actively investigating opportunities to improve performance of other pandemic vaccines including against COVID-19, as well as a broad range of non-pandemic infectious disease vaccines.
Under the terms of the $22 million award from BARDA, Vaxxas will perform a phase 1 clinical study delivering pandemic influenza vaccine to more than 400 people using both unadjuvanted and adjuvanted vaccine formulations. The total cost of this project is estimated to be $24.1 million of which 8.5 percent or $2.1 million will be contributed by Vaxxas.
Pandemic influenza vaccine was selected for this clinical validation study to comprehensively baseline the immune responses and safety of the novel HD-MAP vaccination platform when used for pandemic preparedness and response.
Vaxxas’ HD-MAP platform has clinically shown the potential to transform vaccine delivery with lower dose requirements, enabling more patient-doses to be manufactured more quickly from limited vaccine supply. In addition, the Vaxxas HD-MAP patch enables faster immune onset kinetics and higher antibody responses, potentially resulting in more rapid and durable disease protection; and vaccines that do not need refrigeration, enabling rapid distribution using population-scale logistics such as USPS, UPS, FedEx and more. Unlike needle/syringe, the HD-MAP patch is easy to apply, with studies currently underway to demonstrate self-administration.